Adial Pharmaceuticals, Inc. Accrued Liabilities, Current
Adial Pharmaceuticals, Inc. (ADIL) had Accrued Liabilities, Current of $2.50 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Liabilities, Current $2.50M.
- 2026-03-31: Accrued Liabilities, Current $936.50K.
- 2025-12-31: Accrued Liabilities, Current $742.00K; Accrued Liabilities, Current as first filed $741.70K.
- 2025-09-30: Accrued Liabilities, Current $598.47K.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.50M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $936.50K 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $742.00K 10-Q · filed 2026-08-14 | $741.70K 10-K · filed 2026-03-05 |
| 2025-09-30 | $598.47K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $539.91K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $758.70K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $677.46K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $500.93K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $335.16K 10-Q · filed 2024-08-13 | |
| 2023-12-31 | $477.75K 10-K · filed 2025-03-04 | |
| 2023-09-30 | $408.61K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $324.41K 10-Q/A · filed 2023-10-30 | |
| 2023-03-31 | $1.18M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $963.33K 10-K · filed 2024-04-01 | $1.15M 10-K · filed 2023-03-30 |
| 2022-09-30 | $955.40K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $1.01M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $1.69M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $2.38M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $1.72M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $1.69M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $1.33M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $856.64K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $845.59K 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $239.52K 10-Q · filed 2020-08-13 | |
| 2020-03-31 | $193.45K 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $348.85K 10-K · filed 2021-03-22 | |
| 2018-12-31 | $158.30K 10-K · filed 2020-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |